Total amount: € 0,00
HOW TO ORDER
A Journal on Angiology
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
International Angiology 2017 Mar 14
Copyright © 2017 EDIZIONI MINERVA MEDICA
Comparison of clinical outcomes of pharmacomechanical thrombectomy in iliac vein thrombosis with and without may-thurner syndrome
In-Sub KIM 1, Won-Min JO 1 ✉, Hwan-Hoon CHUNG 2, Seung-Hwa LEE 2
1 Department of Thoracic and Cardiovascular Surgery, Ansan Hospital, Korea University Medical Center, Postgraduate School, Korea University College of Medicine, Ansan City, Korea; 2 Department of Radiology, Ansan Hospital, Korea University Medical Center, Korea University College of Medicine, Ansan City, Korea
BACKGROUND: May-Thurner syndrome (MTS) has a different etiology from that of general deep vein thrombosis (DVT). However, few clinical comparisons of MTS-induced and non-MTS- induced DVT have been reported. The aim of this study was to analyze the clinical results of pharmacomechanical thrombectomy (PMT) in DVT with and without MTS.
METHODS: Forty-seven iliac-vein thrombosis patients treated with PMT between January 2008 and December 2013 were enrolled. 25 patients had DVT with MTS and 22 patients had iliac vein DVT without MTS. We retrospectively reviewed medical records and analyzed mid-term patencies and post-thrombotic syndrome (PTS) occurrence by Villalta score.
RESULTS: The median follow-up period was 48.4 (36~92) months. A venous stent was inserted in the iliac vein in all MTS patients. One-/two-/three-year primary patencies in the non-MTS group were 77.3% (n=17) for all three years in the non-MTS group and were 96.0% (n=24), 83.1% (n=22), and 83.1% (n=22) in the MTS group for years 1/2/3, respectively. One-/two-/three- year secondary patencies were 90.9% (n=20) for all three years in the non-MTS group and were 96.0% (n=24), 91.4% (n=23), and 91.4% (n=23) in the MTS group, respectively. One- /two-/three-year Villalta scores were 4.3, 3.9, and 3.4 in the non-MTS group, and 3.8, 3.7, and 4.0 in the MTS group. Primary/second patency and Villalta score were not significantly different between the MTS and non-MTS groups.
CONCLUSIONS: Although MTS and DVT have different etiologies, clinical results for both diseases using PMT were not significantly different. Therefore, PMT can be offered as an acceptable initial therapy in DVT patients with and without MTS.
KEY WORDS: May thurner syndrome - Deep vein thrombosis - Thrombectomy - Post-thrombotic syndrome